Imvax
Philadelphia, US · Founded 2015 · Delaware corporation
Find your way into Imvax
882 people in our graph share verified history with the Imvax team — schools, employers, funds. One of them is your warm intro.
Anthony Philippakisunlockedknows Mark A. Exley · together at Brigham and Women's Hospital, Harvard Medical School (overlapped)
knows the team · via King's College London
×2knows the team · via Adaptimmune
knows the team · via Imperial College London
×2knows the team · via Brigham and Women's Hospital, Harvard Medical School
×2knows the team · via Beth Israel Deaconess Med. Ctr. Harvard Medical School
Imvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.
Founders & leadership
Imvax was founded in 2015 by Peter B. Corr and David W. Andrews.
PB
Peter B. CorrCo-Founder
DW
David W. AndrewsCo-Founder & former Chief Medical Officer
JP
John P. FureyinExecutive Chairman of the Board (former CEO)John P. Furey is Executive Chairman at Imvax, a clinical-stage biopharmaceutical company developing immunotherapies for solid tumors. With three decades of experience in the pharmaceutical and vaccine sectors across multiple continents, he holds board positions at Vaxcyte, Sensorion, and Adaptimmune.
SP
Sean P. HemingwayinChief Operating Officer
JM
John M. LimongelliinChief Financial Officer and Chief Legal OfficerJohn M. Limongelli is Chief Financial Officer and Chief Legal Officer at Imvax. He brings over two decades of public company experience, with background in securities law, corporate governance, mergers and acquisitions, and employment law.
MA
Mark A. ExleyinFormer Chief Scientific OfficerMark A. Exley is a cellular and molecular immunologist with over 20 years of academic research experience and 14+ years in biotech translating immunology research to clinical applications; he previously served as Chief Scientific Officer at Imvax and co-founded NKT Therapeutics, with work focused on natural killer T cell characterization and cell-based immunotherapy development.
AW
Arthur W HoweNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$151.8M disclosed across 3 of 6 rounds · 2017–2025
▶$112.4MraisedJul 2020 · 19 investors · BiotechnologyRule 506(b)
▶$112.4MraisedJul 2020 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven AltschulerDirector
- David AndrewsExecutive Officer, Director
- John FureyExecutive Officer, Director
- Arthur W HoweExecutive Officer
- David BunningDirector
- Thomas PfistererDirector
- Peter CorrExecutive Officer, Director
- Ted KoutouzisDirector
- Ira BrindDirector
- Wendy DiCiccoDirector
- Offering amount
- $112.4M
- Amount sold
- $112.4M
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$24.8MraisedMay 2019 · 16 investors · BiotechnologyRule 506(b)
▶$24.8MraisedMay 2019 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David BunningDirector
- Thomas PfistererDirector
- Ted KoutouzisDirector
- Peter CorrExecutive Officer, Director
- David AndrewsExecutive Officer, Director
- Arthur W HoweExecutive Officer, Director
- Steven AltschulerDirector
- Offering amount
- $25.1M
- Amount sold
- $24.8M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$14.7MraisedJun 2017 · 11 investors · BiotechnologyRule 506(b)
▶$14.7MraisedJun 2017 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David AndrewsExecutive Officer, Director
- Peter CorrDirector
- Arthur W HoweExecutive Officer, Director
- Offering amount
- $15M
- Amount sold
- $14.7M
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld62 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Vaccinex53 shared keywordsVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
Companies competing with Imvax for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Imvax do?
- Imvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.
- Who founded Imvax?
- Imvax was founded by Peter B. Corr, David W. Andrews in 2015.
- How much funding has Imvax raised?
- Imvax has disclosed $151.8M raised across 3 of its 6 known rounds.
- Where is Imvax headquartered?
- Imvax is headquartered in Philadelphia, US.